Candel Therapeutics press release (NASDAQ:CADL): Q1 GAAP EPS of -$0.28. Cash and cash equivalents, as of March 31, 2024, were $25.7 million, as compared to $35.4 million as of December 31, 2023. Based...
Source LinkCandel Therapeutics press release (NASDAQ:CADL): Q1 GAAP EPS of -$0.28. Cash and cash equivalents, as of March 31, 2024, were $25.7 million, as compared to $35.4 million as of December 31, 2023. Based...
Source Link
Comments